Cyclosporin trough concentration-rejection relationship after kidney transplantation

Indian Journal of Pharmacology

Volumn 35, Issue 6, 2003, Pages 395-396

  Tolou Ghamari, Z ^a   Palizban, A ^a   Gharavi, M ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYCLOSPORIN; CYTOCHROME A; CYTOCHROME P450 3A4; DRUG METABOLITE; MONOCLONAL ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; BODY WEIGHT; CHRONIC GRAFT REJECTION; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EXCRETION; DRUG EXPOSURE; ENZYME ACTIVITY; FEMALE; GENETIC HETEROGENEITY; HUMAN; IMMUNOLOGICAL PARAMETERS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; LETTER; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; RADIOIMMUNOASSAY; RANK SUM TEST; RECIPIENT; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE;

EID: 0345528191     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (10)

1. Inoue S, Beck Y, Nagao T, Uchida H. Early fluctuation in cyclosporine A trough levels affects long-term outcome of kidney transplants. Transplant Proc 1994;26:2571-3.
2. Min DI, Perry PJ, Chen HY. Cyclosporin trough concentrations in predicting allograft rejection and renal toxicity up to 12 months after renal transplantation. Pharmacotherapy 1998;18:282-7.
3. Tejani A, Emmett L. Acute and chronic rejection. Semin Nephrol 2001;21:498-507.
4. Tolou-Ghamari Z. Monitoring tacrolimus in liver transplant recipients: A consideration of alternative techniques and the influence of clinical status. PhD Thesis. University of London. 1999.
5. Tolou-Ghamari Z, Wendon J, Tredger JM. In vitro pentamer formation as a biomarker of tacrolimus-related immunosuppressive activity after liver transplantation. Clin Chem Lab Med 2000;38:1209-11.
6. Sewing KF, Christians U, Kohlhaw K, Radeke H, Strohmeyer S, Kownatzki R, et al. Biologic activity of cyclosporine metabolites. Transplant Proc 1990;22:1129-34.
7. Christians U, Bleck JS, Lampen A, Barder A, Thiesemann C, Klien V, et al. Are cytochrome P450 3A enzymes in the small intestine responsible for different cyclosporine metabolite patterns in stable male and female renal allograft recipients after co-administration of diltiazem? Transplant Proc 1996;28:2159-61.
8. Gjertson DW. Impact of delayed graft function and acute rejection on graft survival. Transplant Proc 2002;34:2432.
9. Soin AS, Rasmussen A, Jamieson NV, Watson CJ, Friend PJ, Wight DG, et al. Cyclosporin levels in the early posttransplant period - Predictive of chronic rejection in liver transplantation. Transplantation 1995;59:1119-23.
10. Tan KK, Trull AK, Hue KL, Best NG, Wallwork J, Higenbottam TW. Pharmacokinetics of cyclosporin in heart and lung transplantation candidates and recipients with cystic fibrosis and Eisenmenger syndrome. Clin Pharmacol Ther 1993;53:544-54.